Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel
Information source: University of Southern Denmark
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: CYP2C19 Genotypes
Intervention: Proguanil (Drug); Clopidogrel (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: University of Southern Denmark
Summary
The aim of this study is to investigate if the genetic variant CYP2C19*17 affects the
pharmacokinetics of proguanil and clopidogrel.
Clinical Details
Official title: Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Proguanil pharmacokinetics. Primary endpoint is cycloguanil formation clearance.
Secondary outcome: Pharmacokinetics of the derivatised active clopidogrel metabolite.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy volunteers
- Written consent
- Age 18-65
- CYP2C19*1 and or CYP2C19*17 genotype.
Exclusion Criteria:
- Daily medication
- Alcohol abuse
- Pregnancy
- Breastfeeding
Locations and Contacts
Clinical Pharmacology, University of Southern Denmark, Odense, Fyn DK-5000, Denmark
Additional Information
Starting date: October 2011
Last updated: July 2, 2013
|